Which has the lower trailing P/E, DXCM or EW?

DXCM has the lower trailing P/E: DXCM trades at 35.39 and EW at 52.89. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, DXCM or EW?

Over the past five years, DXCM grew revenue faster — DXCM at a 18.03% CAGR versus EW at 5.75%.

Is DXCM or EW more profitable?

DXCM runs the higher net margin — DXCM at 20.12% versus EW at 15.43%.

How have DXCM and EW total returns compared?

Over the past 10 years, DXCM delivered 14.70% and EW delivered 9.25% annualized total return. Past performance doesn't predict future results.

DexCom, Inc. (DXCM) vs Edwards Lifesciences Corporation (EW)

A side-by-side comparison of DexCom, Inc. and Edwards Lifesciences Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 12, 2026. Differences are shown without an overall score or investment verdict.

DXCM

DexCom, Inc.

$33.69B

$89.27HealthcareDelayed quote: Aug 12, 2026, 9:45 AM EDT

Edwards Lifesciences Corporation

$53.35B

$92.65HealthcareDelayed quote: Aug 12, 2026, 9:45 AM EDT

Total return — DXCM vs EW

growth of $100 · dividends reinvested · last 10y

DXCM +283.3% (+14.4%/yr)EW +144.9% (+9.4%/yr)DXCM compounded faster over this window

DXCM EW

DXCM vs EW: by the numbers

•EW is the larger company ($53.35B vs $33.69B market cap).
•DXCM trades at the lower trailing earnings multiple (35.39 vs 52.89 P/E), one valuation lens rather than an overall verdict.
•DXCM converts more revenue to profit (20.12% vs 15.43% net margin).
•DXCM grew revenue faster over the past five years (18.03% vs 5.75% CAGR).

Metrics side by side

Valuation

Metric	DXCM	EW
P/E ratio	35.39	52.89
Forward P/E	33.69	30.67
P/S ratio	7.06	8.16
P/B ratio	13.38	5.01
EV / EBITDA	25.21	25.54
FCF yield	4.00%	2.70%

Profitability

Metric	DXCM	EW
Gross margin	62.47%	77.98%
Operating margin	22.92%	28.09%
Net margin	20.12%	15.43%
ROE	38.14%	9.46%
ROIC	16.61%	11.40%

Growth (annualized)

Metric	DXCM	EW
Revenue CAGR (5Y)	18.03%	5.75%
EPS CAGR (5Y)	10.31%	6.87%
FCF CAGR (5Y)	69.49%	6.41%
Total return CAGR (5Y)	-6.09%	-3.84%

Frequently asked

Which has the lower trailing P/E, DXCM or EW?: DXCM has the lower trailing P/E: DXCM trades at 35.39 and EW at 52.89. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, DXCM or EW?: Over the past five years, DXCM grew revenue faster — DXCM at a 18.03% CAGR versus EW at 5.75%.
Is DXCM or EW more profitable?: DXCM runs the higher net margin — DXCM at 20.12% versus EW at 15.43%.
How have DXCM and EW total returns compared?: Over the past 10 years, DXCM delivered 14.70% and EW delivered 9.25% annualized total return. Past performance doesn't predict future results.

Go deeper

Full DXCM analysis Full EW analysis Interactive comparison tool

Dig into the metrics

DexCom P/E ratio Edwards Lifesciences P/E ratio DexCom ROE Edwards Lifesciences ROE DexCom operating margin Edwards Lifesciences operating margin DexCom revenue growth Edwards Lifesciences revenue growth DexCom free cash flow Edwards Lifesciences free cash flow

DexCom & Edwards Lifesciences appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 12, 2026.